Cargando…

In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant

Loss-of-function mutations in the cardiac Na(+) channel α-subunit Na(v)1.5, encoded by SCN5A, cause Brugada syndrome (BrS), a hereditary disease characterized by sudden cardiac death due to ventricular fibrillation. We previously evidenced in vitro the dominant-negative effect of the BrS Na(v)1.5-R1...

Descripción completa

Detalles Bibliográficos
Autores principales: Doisne, Nicolas, Grauso, Marta, Mougenot, Nathalie, Clergue, Michel, Souil, Charlotte, Coulombe, Alain, Guicheney, Pascale, Neyroud, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195286/
https://www.ncbi.nlm.nih.gov/pubmed/34122134
http://dx.doi.org/10.3389/fphys.2021.661413
_version_ 1783706475221221376
author Doisne, Nicolas
Grauso, Marta
Mougenot, Nathalie
Clergue, Michel
Souil, Charlotte
Coulombe, Alain
Guicheney, Pascale
Neyroud, Nathalie
author_facet Doisne, Nicolas
Grauso, Marta
Mougenot, Nathalie
Clergue, Michel
Souil, Charlotte
Coulombe, Alain
Guicheney, Pascale
Neyroud, Nathalie
author_sort Doisne, Nicolas
collection PubMed
description Loss-of-function mutations in the cardiac Na(+) channel α-subunit Na(v)1.5, encoded by SCN5A, cause Brugada syndrome (BrS), a hereditary disease characterized by sudden cardiac death due to ventricular fibrillation. We previously evidenced in vitro the dominant-negative effect of the BrS Na(v)1.5-R104W variant, inducing retention of wild-type (WT) channels and leading to a drastic reduction of the resulting Na(+) current (I(Na)). To explore this dominant-negative effect in vivo, we created a murine model using adeno-associated viruses (AAVs). METHODS: Due to the large size of SCN5A, a dual AAV vector strategy was used combining viral DNA recombination and trans-splicing. Mice were injected with two AAV serotypes capsid 9: one packaging the cardiac specific troponin-T promoter, the 5′ half of hSCN5A cDNA, a splicing donor site and a recombinogenic sequence; and another packaging the complementary recombinogenic sequence, a splicing acceptor site, the 3′ half of hSCN5A cDNA fused to the gfp gene sequence, and the SV40 polyA signal. Eight weeks after AAV systemic injection in wild-type (WT) mice, echocardiography and ECG were recorded and mice were sacrificed. The full-length hSCN5A-gfp expression was assessed by western blot and immunohistochemistry in transduced heart tissues and the Na(+) current was recorded by the patch-clamp technique in isolated adult GFP-expressing heart cells. RESULTS: Almost 75% of the cardiomyocytes were transduced in hearts of mice injected with hNa(v)1.5 and ∼30% in hNa(v)1.5-R104W overexpressing tissues. In ventricular mice cardiomyocytes expressing R104W mutant channels, the endogenous I(Na) was significantly decreased. Moreover, overexpression of R104W channels in normal hearts led to a decrease of total Na(v)1.5 expression. The R104W mutant also induced a slight dilatation of mice left ventricles and a prolongation of RR interval and P-wave duration in transduced mice. Altogether, our results demonstrated an in vivo dominant-negative effect of defective R104W channels on endogenous ones. CONCLUSION: Using a trans-splicing and viral DNA recombination strategy to overexpress the Na(+) channel in mouse hearts allowed us to demonstrate in vivo the dominant-negative effect of a BrS variant identified in the N-terminus of Na(v)1.5.
format Online
Article
Text
id pubmed-8195286
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81952862021-06-12 In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant Doisne, Nicolas Grauso, Marta Mougenot, Nathalie Clergue, Michel Souil, Charlotte Coulombe, Alain Guicheney, Pascale Neyroud, Nathalie Front Physiol Physiology Loss-of-function mutations in the cardiac Na(+) channel α-subunit Na(v)1.5, encoded by SCN5A, cause Brugada syndrome (BrS), a hereditary disease characterized by sudden cardiac death due to ventricular fibrillation. We previously evidenced in vitro the dominant-negative effect of the BrS Na(v)1.5-R104W variant, inducing retention of wild-type (WT) channels and leading to a drastic reduction of the resulting Na(+) current (I(Na)). To explore this dominant-negative effect in vivo, we created a murine model using adeno-associated viruses (AAVs). METHODS: Due to the large size of SCN5A, a dual AAV vector strategy was used combining viral DNA recombination and trans-splicing. Mice were injected with two AAV serotypes capsid 9: one packaging the cardiac specific troponin-T promoter, the 5′ half of hSCN5A cDNA, a splicing donor site and a recombinogenic sequence; and another packaging the complementary recombinogenic sequence, a splicing acceptor site, the 3′ half of hSCN5A cDNA fused to the gfp gene sequence, and the SV40 polyA signal. Eight weeks after AAV systemic injection in wild-type (WT) mice, echocardiography and ECG were recorded and mice were sacrificed. The full-length hSCN5A-gfp expression was assessed by western blot and immunohistochemistry in transduced heart tissues and the Na(+) current was recorded by the patch-clamp technique in isolated adult GFP-expressing heart cells. RESULTS: Almost 75% of the cardiomyocytes were transduced in hearts of mice injected with hNa(v)1.5 and ∼30% in hNa(v)1.5-R104W overexpressing tissues. In ventricular mice cardiomyocytes expressing R104W mutant channels, the endogenous I(Na) was significantly decreased. Moreover, overexpression of R104W channels in normal hearts led to a decrease of total Na(v)1.5 expression. The R104W mutant also induced a slight dilatation of mice left ventricles and a prolongation of RR interval and P-wave duration in transduced mice. Altogether, our results demonstrated an in vivo dominant-negative effect of defective R104W channels on endogenous ones. CONCLUSION: Using a trans-splicing and viral DNA recombination strategy to overexpress the Na(+) channel in mouse hearts allowed us to demonstrate in vivo the dominant-negative effect of a BrS variant identified in the N-terminus of Na(v)1.5. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8195286/ /pubmed/34122134 http://dx.doi.org/10.3389/fphys.2021.661413 Text en Copyright © 2021 Doisne, Grauso, Mougenot, Clergue, Souil, Coulombe, Guicheney and Neyroud. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Doisne, Nicolas
Grauso, Marta
Mougenot, Nathalie
Clergue, Michel
Souil, Charlotte
Coulombe, Alain
Guicheney, Pascale
Neyroud, Nathalie
In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
title In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
title_full In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
title_fullStr In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
title_full_unstemmed In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
title_short In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant
title_sort in vivo dominant-negative effect of an scn5a brugada syndrome variant
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195286/
https://www.ncbi.nlm.nih.gov/pubmed/34122134
http://dx.doi.org/10.3389/fphys.2021.661413
work_keys_str_mv AT doisnenicolas invivodominantnegativeeffectofanscn5abrugadasyndromevariant
AT grausomarta invivodominantnegativeeffectofanscn5abrugadasyndromevariant
AT mougenotnathalie invivodominantnegativeeffectofanscn5abrugadasyndromevariant
AT clerguemichel invivodominantnegativeeffectofanscn5abrugadasyndromevariant
AT souilcharlotte invivodominantnegativeeffectofanscn5abrugadasyndromevariant
AT coulombealain invivodominantnegativeeffectofanscn5abrugadasyndromevariant
AT guicheneypascale invivodominantnegativeeffectofanscn5abrugadasyndromevariant
AT neyroudnathalie invivodominantnegativeeffectofanscn5abrugadasyndromevariant